Table 2.

Characteristics and Genomic Alterations in Pre- and Post-EGFR TKIs Samples in Patients With a Fusion at EGFR TKI Progression

Case	Age/Sex	EGFR TKI/Line Before Resistance Biopsy	Genomic Alterations Pre-EGFR TKI (TGPS on Tissue)	Genomic Alterations on Tissue at EGFR TKI Progression (TGPS, CGH Array, and WES-RNAseq on Tissue)
				Fusion	Other Alterations
MR 04	62/F	Gefitinib/2	EGFR: L858R EGFR exon 18, I706Y CTNNB1: S33C NOTCH4: G1821E	EIF4G2-GAB1a	EGFR: L858Ra,b EGFR: I706Ta,b MET: R988Cc EGFR: T790Mc NOTCH4: G1821Eb CTNNB1: G34Va FGFR3: S804Ac BRD4: R1329Qa GATA2: D184Aa WT1: S255Aa TSC1: T1020Pa PDPK1 ampd
MR 211	57/F	Osimertinib/4	EGFR exon 19 del EGFR: T790M TP53 lossd CDK4 ampd HMGA2 ampd MDM2 ampd	FGFR3-TACC3a	EGFR exon 19 dela,b CDK4 ampa,d HMGA2 ampd MDM2 ampa,d TP53 lossd MAP3K7: p.Asp211Hisa GATA3: p.Thr156Proa
MR 393	64/F	Osimertinib/1	EGFR: L858R	FGFR3-TACC3a	EGFR exon 21, L858Ra PIK3R1 muta MYCN: Pro345Thra FANCA: p.Pro1220Arga
MR 48	51/F	Osimertinib/8	EGFR exon 19 del EGFR: T790M TP53: C238F	KIF5B-RETa	EGFR exon 19 dela,b TP53: C238Fa,b
MR 240	65/F	Osimertinib/2	EGFR exon 19 del EGFR: T790Mc CDKN2A muta,c FGFR2: S252Sc TP53 mutc	STRN-ALKa,d	EGFR exon 19 dela,b EGFR: T790Ma,b TP53: p.Lys132fa,b PTEN: F278Lb TERT ampd
MR 01	54/M	Osimertinib/3	EGFR exon 19 del EGFR: T790M TP53 mut	DHHC20-BRAFa	EGFR exon 19 dela,b TP53: Cys135Serfsa,b ERBB2 ampa,d CDK12 ampa

CGH, comparative genomic hybridization; ctDNA circulating tumor DNA; F, female; M, male; RNA-seq, RNA sequencing; TGPS, targeted gene panel sequencing; TKI, tyrosine kinase inhibitor; WES, whole-exome sequencing; Amp, amplification; MR, patient number.

^aGenomic alterations found in WES-RNAseq analyses.

^bGenomic alterations found in TGPS analyses.

^cGenomic alterations found only in the ctDNA analyses.

^dGenomic alterations found in cytoscan HD CGH array.